nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Immune system disorder—Melphalan—peripheral nervous system neoplasm	0.00377	0.00377	CcSEcCtD
Oritavancin—Mediastinal disorder—Melphalan—peripheral nervous system neoplasm	0.00376	0.00376	CcSEcCtD
Oritavancin—Malnutrition—Topotecan—peripheral nervous system neoplasm	0.00371	0.00371	CcSEcCtD
Oritavancin—Malnutrition—Tretinoin—peripheral nervous system neoplasm	0.00368	0.00368	CcSEcCtD
Oritavancin—Malnutrition—Isotretinoin—peripheral nervous system neoplasm	0.00368	0.00368	CcSEcCtD
Oritavancin—Infestation NOS—Alitretinoin—peripheral nervous system neoplasm	0.00357	0.00357	CcSEcCtD
Oritavancin—Infestation—Alitretinoin—peripheral nervous system neoplasm	0.00357	0.00357	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Cisplatin—peripheral nervous system neoplasm	0.00355	0.00355	CcSEcCtD
Oritavancin—Abscess—Epirubicin—peripheral nervous system neoplasm	0.00353	0.00353	CcSEcCtD
Oritavancin—Anaemia—Topotecan—peripheral nervous system neoplasm	0.00343	0.00343	CcSEcCtD
Oritavancin—Anaemia—Tretinoin—peripheral nervous system neoplasm	0.0034	0.0034	CcSEcCtD
Oritavancin—Anaemia—Isotretinoin—peripheral nervous system neoplasm	0.0034	0.0034	CcSEcCtD
Oritavancin—Angioedema—Topotecan—peripheral nervous system neoplasm	0.00339	0.00339	CcSEcCtD
Oritavancin—Anaemia—Melphalan—peripheral nervous system neoplasm	0.00336	0.00336	CcSEcCtD
Oritavancin—Erythema multiforme—Dactinomycin—peripheral nervous system neoplasm	0.00327	0.00327	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—peripheral nervous system neoplasm	0.00327	0.00327	CcSEcCtD
Oritavancin—Extravasation—Epirubicin—peripheral nervous system neoplasm	0.0032	0.0032	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Etoposide—peripheral nervous system neoplasm	0.00319	0.00319	CcSEcCtD
Oritavancin—Myalgia—Topotecan—peripheral nervous system neoplasm	0.00316	0.00316	CcSEcCtD
Oritavancin—Oedema peripheral—Alitretinoin—peripheral nervous system neoplasm	0.00316	0.00316	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—peripheral nervous system neoplasm	0.00314	0.00314	CcSEcCtD
Oritavancin—Myalgia—Isotretinoin—peripheral nervous system neoplasm	0.00313	0.00313	CcSEcCtD
Oritavancin—Myalgia—Tretinoin—peripheral nervous system neoplasm	0.00313	0.00313	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.00311	0.00311	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.00311	0.00311	CcSEcCtD
Oritavancin—Myalgia—Melphalan—peripheral nervous system neoplasm	0.00309	0.00309	CcSEcCtD
Oritavancin—Bronchospasm—Etoposide—peripheral nervous system neoplasm	0.00307	0.00307	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.00307	0.00307	CcSEcCtD
Oritavancin—Cellulitis—Epirubicin—peripheral nervous system neoplasm	0.00307	0.00307	CcSEcCtD
Oritavancin—Connective tissue disorder—Vincristine—peripheral nervous system neoplasm	0.00303	0.00303	CcSEcCtD
Oritavancin—Erythema multiforme—Alitretinoin—peripheral nervous system neoplasm	0.00303	0.00303	CcSEcCtD
Oritavancin—Hyperuricaemia—Epirubicin—peripheral nervous system neoplasm	0.00301	0.00301	CcSEcCtD
Oritavancin—Infection—Topotecan—peripheral nervous system neoplasm	0.00301	0.00301	CcSEcCtD
Oritavancin—Infection—Isotretinoin—peripheral nervous system neoplasm	0.00298	0.00298	CcSEcCtD
Oritavancin—Infection—Tretinoin—peripheral nervous system neoplasm	0.00298	0.00298	CcSEcCtD
Oritavancin—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.00297	0.00297	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—peripheral nervous system neoplasm	0.00296	0.00296	CcSEcCtD
Oritavancin—Blood bilirubin increased—Epirubicin—peripheral nervous system neoplasm	0.00295	0.00295	CcSEcCtD
Oritavancin—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.00295	0.00295	CcSEcCtD
Oritavancin—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.00295	0.00295	CcSEcCtD
Oritavancin—Infection—Melphalan—peripheral nervous system neoplasm	0.00295	0.00295	CcSEcCtD
Oritavancin—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.00294	0.00294	CcSEcCtD
Oritavancin—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00293	0.00293	CcSEcCtD
Oritavancin—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00293	0.00293	CcSEcCtD
Oritavancin—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.00292	0.00292	CcSEcCtD
Oritavancin—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.00292	0.00292	CcSEcCtD
Oritavancin—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00289	0.00289	CcSEcCtD
Oritavancin—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.00288	0.00288	CcSEcCtD
Oritavancin—Cardiac disorder—Vincristine—peripheral nervous system neoplasm	0.00287	0.00287	CcSEcCtD
Oritavancin—Blood uric acid increased—Epirubicin—peripheral nervous system neoplasm	0.00284	0.00284	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—peripheral nervous system neoplasm	0.00284	0.00284	CcSEcCtD
Oritavancin—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.00279	0.00279	CcSEcCtD
Oritavancin—Infestation NOS—Etoposide—peripheral nervous system neoplasm	0.00279	0.00279	CcSEcCtD
Oritavancin—Infestation—Etoposide—peripheral nervous system neoplasm	0.00279	0.00279	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—peripheral nervous system neoplasm	0.00279	0.00279	CcSEcCtD
Oritavancin—Mediastinal disorder—Vincristine—peripheral nervous system neoplasm	0.00278	0.00278	CcSEcCtD
Oritavancin—Anaemia—Dactinomycin—peripheral nervous system neoplasm	0.00278	0.00278	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.00276	0.00276	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.00274	0.00274	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.00274	0.00274	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—peripheral nervous system neoplasm	0.00273	0.00273	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.0027	0.0027	CcSEcCtD
Oritavancin—Connective tissue disorder—Cisplatin—peripheral nervous system neoplasm	0.00268	0.00268	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—peripheral nervous system neoplasm	0.00263	0.00263	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.00261	0.00261	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00259	0.00259	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00259	0.00259	CcSEcCtD
Oritavancin—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.00258	0.00258	CcSEcCtD
Oritavancin—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.00256	0.00256	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.00256	0.00256	CcSEcCtD
Oritavancin—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.00253	0.00253	CcSEcCtD
Oritavancin—Anaemia—Vincristine—peripheral nervous system neoplasm	0.00248	0.00248	CcSEcCtD
Oritavancin—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.00247	0.00247	CcSEcCtD
Oritavancin—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00246	0.00246	CcSEcCtD
Oritavancin—Infection—Dactinomycin—peripheral nervous system neoplasm	0.00244	0.00244	CcSEcCtD
Oritavancin—Urticaria—Topotecan—peripheral nervous system neoplasm	0.00241	0.00241	CcSEcCtD
Oritavancin—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00239	0.00239	CcSEcCtD
Oritavancin—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00239	0.00239	CcSEcCtD
Oritavancin—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.00238	0.00238	CcSEcCtD
Oritavancin—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.00238	0.00238	CcSEcCtD
Oritavancin—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.00237	0.00237	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.00236	0.00236	CcSEcCtD
Oritavancin—Urticaria—Melphalan—peripheral nervous system neoplasm	0.00236	0.00236	CcSEcCtD
Oritavancin—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.00232	0.00232	CcSEcCtD
Oritavancin—Myalgia—Vincristine—peripheral nervous system neoplasm	0.00229	0.00229	CcSEcCtD
Oritavancin—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00226	0.00226	CcSEcCtD
Oritavancin—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.00226	0.00226	CcSEcCtD
Oritavancin—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.00225	0.00225	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00224	0.00224	CcSEcCtD
Oritavancin—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00223	0.00223	CcSEcCtD
Oritavancin—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.00223	0.00223	CcSEcCtD
Oritavancin—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00222	0.00222	CcSEcCtD
Oritavancin—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00221	0.00221	CcSEcCtD
Oritavancin—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00221	0.00221	CcSEcCtD
Oritavancin—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.00221	0.00221	CcSEcCtD
Oritavancin—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.0022	0.0022	CcSEcCtD
Oritavancin—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00218	0.00218	CcSEcCtD
Oritavancin—Infection—Vincristine—peripheral nervous system neoplasm	0.00218	0.00218	CcSEcCtD
Oritavancin—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00215	0.00215	CcSEcCtD
Oritavancin—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00214	0.00214	CcSEcCtD
Oritavancin—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00213	0.00213	CcSEcCtD
Oritavancin—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00213	0.00213	CcSEcCtD
Oritavancin—Pruritus—Melphalan—peripheral nervous system neoplasm	0.0021	0.0021	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00208	0.00208	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00207	0.00207	CcSEcCtD
Oritavancin—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00207	0.00207	CcSEcCtD
Oritavancin—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00206	0.00206	CcSEcCtD
Oritavancin—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00206	0.00206	CcSEcCtD
Oritavancin—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00203	0.00203	CcSEcCtD
Oritavancin—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.00202	0.00202	CcSEcCtD
Oritavancin—Anaemia—Etoposide—peripheral nervous system neoplasm	0.00201	0.00201	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00201	0.00201	CcSEcCtD
Oritavancin—Dizziness—Topotecan—peripheral nervous system neoplasm	0.002	0.002	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.002	0.002	CcSEcCtD
Oritavancin—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00199	0.00199	CcSEcCtD
Oritavancin—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00199	0.00199	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00197	0.00197	CcSEcCtD
Oritavancin—Infection—Cisplatin—peripheral nervous system neoplasm	0.00193	0.00193	CcSEcCtD
Oritavancin—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00193	0.00193	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00192	0.00192	CcSEcCtD
Oritavancin—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00191	0.00191	CcSEcCtD
Oritavancin—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00191	0.00191	CcSEcCtD
Oritavancin—Rash—Topotecan—peripheral nervous system neoplasm	0.00191	0.00191	CcSEcCtD
Oritavancin—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00191	0.00191	CcSEcCtD
Oritavancin—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.0019	0.0019	CcSEcCtD
Oritavancin—Headache—Topotecan—peripheral nervous system neoplasm	0.0019	0.0019	CcSEcCtD
Oritavancin—Rash—Tretinoin—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00189	0.00189	CcSEcCtD
Oritavancin—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.00188	0.00188	CcSEcCtD
Oritavancin—Headache—Tretinoin—peripheral nervous system neoplasm	0.00188	0.00188	CcSEcCtD
Oritavancin—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00188	0.00188	CcSEcCtD
Oritavancin—Rash—Melphalan—peripheral nervous system neoplasm	0.00187	0.00187	CcSEcCtD
Oritavancin—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00187	0.00187	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00184	0.00184	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00183	0.00183	CcSEcCtD
Oritavancin—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00181	0.00181	CcSEcCtD
Oritavancin—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00181	0.00181	CcSEcCtD
Oritavancin—Nausea—Topotecan—peripheral nervous system neoplasm	0.0018	0.0018	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00179	0.00179	CcSEcCtD
Oritavancin—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00178	0.00178	CcSEcCtD
Oritavancin—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00178	0.00178	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00177	0.00177	CcSEcCtD
Oritavancin—Infection—Etoposide—peripheral nervous system neoplasm	0.00177	0.00177	CcSEcCtD
Oritavancin—Nausea—Melphalan—peripheral nervous system neoplasm	0.00176	0.00176	CcSEcCtD
Oritavancin—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00173	0.00173	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.00173	0.00173	CcSEcCtD
Oritavancin—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00173	0.00173	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00169	0.00169	CcSEcCtD
Oritavancin—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00168	0.00168	CcSEcCtD
Oritavancin—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00168	0.00168	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00167	0.00167	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00165	0.00165	CcSEcCtD
Oritavancin—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00162	0.00162	CcSEcCtD
Oritavancin—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00161	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.00161	0.00161	CcSEcCtD
Oritavancin—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00156	0.00156	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00156	0.00156	CcSEcCtD
Oritavancin—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00156	0.00156	CcSEcCtD
Oritavancin—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00156	0.00156	CcSEcCtD
Oritavancin—Rash—Dactinomycin—peripheral nervous system neoplasm	0.00155	0.00155	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00153	0.00153	CcSEcCtD
Oritavancin—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00151	0.00151	CcSEcCtD
Oritavancin—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.0015	0.0015	CcSEcCtD
Oritavancin—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00146	0.00146	CcSEcCtD
Oritavancin—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00145	0.00145	CcSEcCtD
Oritavancin—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00145	0.00145	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00145	0.00145	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00145	0.00145	CcSEcCtD
Oritavancin—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00144	0.00144	CcSEcCtD
Oritavancin—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00143	0.00143	CcSEcCtD
Oritavancin—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00143	0.00143	CcSEcCtD
Oritavancin—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00143	0.00143	CcSEcCtD
Oritavancin—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00141	0.00141	CcSEcCtD
Oritavancin—Vomiting—Vincristine—peripheral nervous system neoplasm	0.0014	0.0014	CcSEcCtD
Oritavancin—Rash—Vincristine—peripheral nervous system neoplasm	0.00138	0.00138	CcSEcCtD
Oritavancin—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00138	0.00138	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00138	0.00138	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.00138	0.00138	CcSEcCtD
Oritavancin—Headache—Vincristine—peripheral nervous system neoplasm	0.00137	0.00137	CcSEcCtD
Oritavancin—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00135	0.00135	CcSEcCtD
Oritavancin—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00133	0.00133	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.00133	0.00133	CcSEcCtD
Oritavancin—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00131	0.00131	CcSEcCtD
Oritavancin—Nausea—Vincristine—peripheral nervous system neoplasm	0.0013	0.0013	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.0013	0.0013	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.00128	0.00128	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.00128	0.00128	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.00127	0.00127	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00126	0.00126	CcSEcCtD
Oritavancin—Pruritus—Etoposide—peripheral nervous system neoplasm	0.00126	0.00126	CcSEcCtD
Oritavancin—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00123	0.00123	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.00123	0.00123	CcSEcCtD
Oritavancin—Rash—Cisplatin—peripheral nervous system neoplasm	0.00122	0.00122	CcSEcCtD
Oritavancin—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00122	0.00122	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.00122	0.00122	CcSEcCtD
Oritavancin—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00122	0.00122	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.0012	0.0012	CcSEcCtD
Oritavancin—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00118	0.00118	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00117	0.00117	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00117	0.00117	CcSEcCtD
Oritavancin—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00115	0.00115	CcSEcCtD
Oritavancin—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00113	0.00113	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.00113	0.00113	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.00113	0.00113	CcSEcCtD
Oritavancin—Rash—Etoposide—peripheral nervous system neoplasm	0.00112	0.00112	CcSEcCtD
Oritavancin—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00112	0.00112	CcSEcCtD
Oritavancin—Headache—Etoposide—peripheral nervous system neoplasm	0.00111	0.00111	CcSEcCtD
Oritavancin—Nausea—Etoposide—peripheral nervous system neoplasm	0.00106	0.00106	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.00104	0.00104	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00104	0.00104	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.00103	0.00103	CcSEcCtD
Oritavancin—Infection—Epirubicin—peripheral nervous system neoplasm	0.00099	0.00099	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000977	0.000977	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000972	0.000972	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000968	0.000968	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000962	0.000962	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000955	0.000955	CcSEcCtD
Oritavancin—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000916	0.000916	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000908	0.000908	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000904	0.000904	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.0009	0.0009	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000895	0.000895	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00086	0.00086	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00084	0.00084	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000796	0.000796	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000792	0.000792	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000734	0.000734	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000732	0.000732	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000705	0.000705	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000682	0.000682	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000679	0.000679	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000659	0.000659	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000652	0.000652	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000633	0.000633	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000631	0.000631	CcSEcCtD
Oritavancin—Rash—Epirubicin—peripheral nervous system neoplasm	0.000628	0.000628	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000628	0.000628	CcSEcCtD
Oritavancin—Headache—Epirubicin—peripheral nervous system neoplasm	0.000624	0.000624	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00061	0.00061	CcSEcCtD
Oritavancin—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000592	0.000592	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000586	0.000586	CcSEcCtD
Oritavancin—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000581	0.000581	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000581	0.000581	CcSEcCtD
Oritavancin—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000578	0.000578	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000548	0.000548	CcSEcCtD
